Shifting Science: Why Some Biotech Firms Are Skipping the U.S. for Trials

It is hard to know how the many changes to the federal government’s support of scientific and medical research will play out. If funding uncertainty causes biotech firms to take their work overseas, what does that say about the state of scientific progress in the U.S.?

The May 2025 article by O’Donnell, published in Reuters, highlights how layoffs, leadership changes, and structural shifts at the FDA during the Trump administration are driving some biotech companies to begin early-stage drug trials outside the U.S.—in places like the EU and Australia—due to concerns over delays in review and approval processes.

➡️ Read the full article